Germany cancer biomarker market is anticipated to grow at a CAGR of 11.8% during the forecast period. Germany has well developed healthcare system and favourable government policies which are driving the global cancer biomarker market in the region. Adoption of specialized procedures to treat cancer, extensive R&D in the cancer treatments and presence of globally renowned major hospitals, research centres and clinics are contributing to the growth of the market. The healthcare expenditure of Germany in 2013 was 11.6% as compared to the OECD average of 8.9%. The healthcare of Germany is driven by the specific mechanisms that determine the utilization of health care in the elderly. In Germany health insurance is mandatory for the entire population Regardless of the type of health insurance, all beneficiaries have has accessed by outpatient physician and non-physician services, hospital care, rehabilitation, dental care, prescription drugs, medical supplies and long-term nursing care.
To Request a Sample of our Report on Germany Cancer Biomarker Market: https://www.omrglobal.com/request-sample/germany-cancer-biomarker-market
Germany has well-developed healthcare infrastructure. A number of organizations has been established in the country regarding research activities, which significantly contributes to the Germany cancer biomarker market. German Cancer Aid was established in 1974, in order to promote research, improve care for cancer patients and increase cancer awareness through information, education and public campaigns. Krebsallianz GmbH is a medical relief program focused on cancer and is funding childhood cancer research in Germany. German Children’s Cancer Foundation is established to provide support, social fund, aftercare, pirate forest camp, cancer information and supporting research in 1995.
Apart from cancer organization, a number of cancers centers has been established. Cancer centers can be defined as hospitals and research institutes cater to a designated region. Some of the major cancer center are Centre for Integrated Oncology (CIO), Charité Comprehensive Cancer Centre, Comprehensive Cancer Centre Erlangen EMN, National Centre for Tumor Diseases (NCT) Heidelberg, Tumor Centre Freiburg, University Centre for Tumor Diseases Frankfurt (UCT), University Cancer Centre Hamburg, West German Tumor Centre. Thus, this is expected to influence the growth of the Germany cancer biomarker market during the forecast period.
(Get 15% Discount on Buying this Report)
A full Report of Germany Cancer Biomarker Market is Available at: https://www.omrglobal.com/industry-reports/germany-cancer-biomarker-market
Germany Cancer Biomarker Market Segmentation
By Biomarker Type
- Genetic Biomarker
- Protein Biomarker
By Cancer Type
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Other
By Applications
- Drug Discovery and Development
- Diagnosis
- Risk Assessment
- Prognostics
By Profiling Technology
- Omics Technology
- Immunoassays
- Cytogenetics
- Bioinformatics
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
